Thailand’s New Cannabis Regulations: A Shift in the Market Landscape
In a significant move that is poised to reshape the cannabis landscape in Thailand, the Ministry of Public Health announced on January 5 that over 7,000 cannabis stores across the nation will be forced to close by 2025. This decision comes in response to a notable decline in license renewal applications following the introduction of a stringent new cannabis management law. Under this law, obtaining cannabis will now require a prescription from a licensed medical professional, fundamentally altering the public’s access to this plant.
The New Cannabis Management Law
The recently approved cannabis management law replaces a previous system implemented in 2016 and aims to establish comprehensive regulations overseeing the research, export, sale, and processing of controlled herbal substances, notably cannabis. This legislative shift underscores Thailand’s commitment to a more structured approach to cannabis use, emphasizing its medicinal applications while tightening restrictions on recreational use.
Changes in Retail Regulations
With this new framework, cannabis vendors are limited to selling their products in designated locations such as medical institutions, pharmacies, herbal medicine stores, and traditional treatment centers. This limitation is designed to ensure that cannabis is distributed safely and within a controlled environment. Importantly, only qualified personnel can dispense cannabis, which necessitates a doctor’s prescription, thereby placing a heavier burden on patients who may have previously accessed cannabis more freely.
Current Landscape of Cannabis Stores
As of late December 2025, Thailand boasted 18,433 cannabis businesses. However, alarming statistics reveal that more than half of these stores—8,636 in total—held expired licenses. Only 1,339 stores, about 15.5%, opted to apply for renewal under the new regulations, indicating a seismic shift in the operational models of these businesses. The remaining 7,297 shops decided to exit the market entirely, reflecting a significant concern regarding the long-term viability of cannabis retail in Thailand under the new rules.
While many cannabis shops can continue their operations until their current licenses expire, all future applications and renewals will be held to the new regulatory standards. This inevitably places pressure on store owners to readjust their business strategies in line with the evolving legal landscape.
The Future of Medical Cannabis
Thai Public Health Minister Pattana Promphat has reassured the public that the country possesses a sufficient number of medical professionals to support the expected shift towards a more regulated cannabis market. He emphasized that despite the regulatory changes, patients utilizing cannabis for legitimate medical purposes will continue to have access without interference. This is a critical point, as many patients rely on cannabis for various health conditions, and the new law aims to ensure that they are not adversely affected by the stricter regulations.
Anticipating Future Developments
Looking ahead, the Ministry of Public Health has projected that 4,587 cannabis stores will see their licenses expire in 2026, followed by another 5,210 in 2027. This ongoing trend suggests a continuous evolution of the industry, as the regulatory framework is likely to impact not just the number of active cannabis businesses but also the overall market dynamics moving forward. As the government implements these new rules, businesses will need to navigate the complexities of compliance while striving to meet consumer needs in a tightening market.
Final Insights
The recent shifts in Thailand’s cannabis regulations mark a pivotal moment in the country’s relationship with this versatile plant. The transition towards a more controlled approach raises essential questions about the future of cannabis use, both in terms of accessibility and the operational realities for cannabis businesses. As the landscape continues to evolve, stakeholders across the board will need to adapt, ensuring that the transition supports both medical users and the integrity of the industry.